Table 3

Results of ELISA using PM1-α peptide with polymyositis/scleroderma and various control sera

Number (%) of anti-PM1-α-positive sera

Mean value/standard deviation

Top value

Polymyositis/scleroderma (n = 40)

22 (55)

3.1/3.2

11.6

Rheumatic disease controls (n = 452)

33 (7.3)

0.6/0.9

7.7

Polymyositis (n = 40)

3 (7.5)

1.0/1.1

7.4

Scleroderma (n = 205)

27 (13.2)

0.9/1.2

7.5

Rheumatoid arthritis (n = 69)

0 (0)

0.3/0.2

1.1

Mixed connective tissue disease (n = 6)

0 (0)

0.4/0.1

0.6

Undifferentiated connective tissue disease (n = 10)

0 (0)

0.3/0.0

0.4

Systemic lupus erythematosus (n = 114)

3 (2.6)

0.5/0.7

7.7

Other rheumatic diseases (n = 8)

0 (0)

0.3/0.1

0.6

Hepatitis C virus (n = 48)

2 (4.2)

0.5/0.5

2.6

Organ specific disorders (n = 23)

0 (0)

0.4/0.2

0.8

Hashimoto thyroiditis (n = 11)

0 (0)

0.3/0.2

0.8

Grave's disease (n = 12)

0 (0)

0.4/0.2

0.8

Healthy individuals (n = 4)

0 (0)

0.6/0.2

0.7

Mahler et al. Arthritis Research & Therapy 2005 7:R704   doi:10.1186/ar1729